Clínica Baviera runs a network of private women's health and fertility clinics in Spain, offering IVF, egg freezing, and related diagnostic and genetic testing services, with the reproductive medicine business forming the core of its revenue. Its edge is a combination of scale within a fragmented Spanish fertility market and a clinical reputation that drives repeat and referral volume, reflected in a 49.8% gross margin and a 21.6% operating margin. Revenue growth of 13.3% is supported by continued demand for assisted reproduction and the growing share of patients paying out of pocket for treatments the public system rations. At 18.9 times trailing earnings but 30.8 times forward, the market is pricing in an expected earnings dip, so the forward multiple is the number to test against the company's margin and volume assumptions. A 45.9% return on equity is high enough to make the balance sheet and any leverage behind it the first thing to check.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:53 CEST | ACCE price target | €56.00 | first publication | €54.20 |
| 22 Oct 2026, 14:04 CEST | Rating | Overvalued | first publication | €54.40 |
| 22 Oct 2026, 14:04 CEST | Fair value | €48.84 | first publication | €54.40 |
Answered from Clínica Baviera, S.A. fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| CBAV.MC Clínica Baviera, S.A. | €53.80 | €49 | 10% above | 18.7x | 45.9% | 85 | 71 |
| CSTL Castle Biosciences Inc. Common Stock | $33.08 | - | - | - | -4.2% | 47 | 55 |
| OPK OPKO Health Inc. Common Stock | $1.63 | - | - | - | -5.9% | 31 | 42 |
| PSNL Personalis Inc. Common Stock | $15.85 | - | - | - | -50.3% | 31 | 48 |
| WGS GeneDx Holdings Corp. Class A Common Stock | $56.15 | - | - | - | -40.8% | 43 | 33 |
| NEO NeoGenomics Inc. Common Stock | $16.59 | - | - | - | -6.3% | 39 | 56 |
| VIMIAN.ST Vimian Group AB (publ) | kr 40.90 | kr 26 | 58% above | 53.8x | 5.3% | 71 | 63 |
Where CBAV.MC ranks against its sector peers on each metric.